Management of menopausal symptoms in women with a history of breast cancer
Early breast cancer
2016
Clinical guidance for the management of lobular carcinoma in situ
Early breast cancer
2016
Hypofractionated radiotherapy for early (operable) breast cancer
Early breast cancer
2015
Clinical guidance for responding to suffering in adults with cancer
Psychosocial care
2014
First-line chemotherapy for the treatment of women with epithelial ovarian cancer
Ovarian cancer
2014
CNS metastases in women with secondary breast cancer
Advanced Breast Cancer
2014
Recommendations for the management of early breast cancer in women with an identified BRCA1 or BRCA2 gene mutation or at high risk of a gene mutation
Early breast cancer
2014
Follow up of women with epithelial ovarian cancer
Ovarian cancer
2012
Recommendations for the identification and management of fear of cancer recurrence in adult cancer survivors
Psychosocial care
2012
Recommendations for use of bisphosphonates in early breast cancer
Early breast cancer
2011
Recommendations for use of hypofractionated radiotherapy in early (operable) breast cancer
Early breast cancer
2011
Recommendations for staging and managing the axilla in early (operable) breast cancer
Early breast cancer
2011
Recommendations for the management of women at high risk of ovarian cancer
Ovarian cancer
2011
Recommendations for use of bisphosphonates for advanced breast cancer
Advanced Breast Cancer
2011
Recommendations for use of chemotherapy for the treatment of advanced breast cancer
Advanced Breast Cancer
2010
Recommendations for follow-up of women with early breast cancer
Early breast cancer
2010
Recommendations for use of Sentinel node biopsy in early (operable) breast cancer
Early breast cancer
2008
Recommendations for use of endocrine therapy for the treatment of hormone receptor-positive advanced breast cancer
Advanced Breast Cancer
2008
Recommendations for use of Taxane-containing chemotherapy regimens for the treatment of early (operable) breast cancer
Early breast cancer
2008
Recommendations for use of Trastuzumab (Herceptin®) for the treatment of HER2-positive breast cancer
Advanced Breast Cancer
2007